Abstract
Atrial fibrillation (AF) is a frequent and costly health care problem, being the most common arrhythmia that leads to hospital admission. The overall prevalence of AF in the United States ranges from less than 1% in young, otherwise healthy individuals up to nearly 9% in elderly patients. AF may cause disabling symptoms and serious adverse effects such as impairment of cardiac function or thromboembolic events. Due to the limited efficacy of antiarrhythmic drugs for AF, several nonpharmacologic options have evolved, including pacemaker therapy, transvenous catheter ablation techniques, surgical procedures, and treatment with an implantable atrial defibrillator (IAD). The high prevalence of AF and its clinical complications, the poor efficacy of medical therapy in preventing recurrences, and dissatisfaction with alternative modes of therapy stimulated interest in an IAD [1]. We report on the worldwide experience with the first IAD, the Metrix system, model 3000 and 3020 (InControl Inc., Redmond, Wash., USA).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lüderitz B, Pfeiffer D, Tebbenjohanns J, Jung W (1966) Nonpharmacologic strategies for treating atrial fibrillation. Am J Cardiol 77:45A-52A
Jung W, Lüderitz B (1997) Implantable atrial defibrillator: which results and indications. In: Raviele A (ed) Cardiac arrhythmias. Springer, Berlin Heidelberg New York, pp 100–109
Jung W, Wolpert C, Esmailzadeh B et al (1998) Specific considerations with the automatic implantable atrial defibrillator. J Cardiovasc Electrophysiol 9:S193–S201
Jung W, Lüderitz B (1997) Implantable atrial defibrillator: quo vadis? (editorial) Pacing Clin Electrophysiol 20:2141–2145
Jung W, Tebbenjohanns J, Wolpert C et al (1995) Safety, efficacy, and pain perception of internal atrial defibrillation in humans. Circulation 92:472 (abstr)
Jung W, Lüderitz B (1998) Quality of life of patients with atrial fibrillation. J Cardiovasc Electrophysiol 9:S177–S186
Lau CP, Tse HF, Lok NS et al (1977) Initial clinical experience with an implantable human atrial defibrillator. Pacing Clin Electrophysiol 20:220–225
Jung W, Kirchhoff PG, Lau CP, Tse HF, Lüderitz B, for the Metrix System Clinical Investigational Group (1997) Therapy delivery with the METRIX automatic atrial defibrillation system: threshold stability and shock safety. J Am Coll Cardiol 29:78A (abstr)
Wellens HJJ, Lau CP, Lüderitz B et al, for the Metrix Investigators (1998) The atrioverter, an implantable device for treatment of atrial fibrillation. Circulation 98:1651–1656
Jung W, Wolpert C, Herwig S et al (1998) Initial experience with the implantable atrial defibrillator. G Ital Cardiol 28 (suppl 1):592–594
Jung W, Wolpert C, Spehl S et al, for the Worldwide Metrix Investigators (1998) Worldwide experience with the Metrix implantable atrial defibrillator. In: Adornato E (ed) Rhythm control from cardiac evaluation to treatment. Edizioni Luigi Pozzi, Rome, pp 139–143
Reuter D, Ayers GM (1998) Future directions of electrotherapy for atrial fibrillation. J Cardiovasc Electrophysiol 9:S202–S210
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Italia
About this paper
Cite this paper
Jung, W., Wolpert, C., Herwig, S., Lüderitz, B. (2000). Implantable Atrial Defibrillator: What Are the Future Perspectives?. In: Raviele, A. (eds) Cardiac Arrhythmias 1999. Springer, Milano. https://doi.org/10.1007/978-88-470-2139-6_16
Download citation
DOI: https://doi.org/10.1007/978-88-470-2139-6_16
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2178-5
Online ISBN: 978-88-470-2139-6
eBook Packages: Springer Book Archive